Teva Pharmaceutical Industries Ltd. (TEVA) reported earnings of 89 cents in the third quarter of 2009, up 16% from the year-ago period and a cent above the Zacks Consensus Estimate. Strong sales of Copaxone and in the respiratory business helped drive earnings in the reported quarter. Net sales increased 25% to $3.55 billion, with the Barr acquisition contributing to sales across different geographical segments. The strengthening U.S. dollar adversely impacted net sales by $160 million or 6%. Revenue performance across key business segments was mixed. While the Pharmaceuticals Sales segment posted growth of 27% with revenues coming in at $3.4 billion, the active pharmaceutical ingredients (API) segment reported an 8% decline in growth with sales coming in at $136 million. Pharmaceutical segment sales were driven by strong performances in the North American, European and International segments. The launch of generic versions of Ortho Tri-Cyclen Lo ...

Bayer (BAYRY) announced its third quarter results yesterday. Revenues of the group recorded a 7% decline to €7.39 billion from €7.94 billion. The company’s earnings per share from continued operations were €0.78, compared to €0.85 in year-ago period.

Bayer operates through three major segments: Healthcare, accounting for 53.24% of total revenues in the third quarter of 2009; CropScience (15.4%), and Material Science (27.5%) with the remaining 4% coming from other items. While Healthcare segment revenues improved marginally by 3.5%, both cropscience and Material Science fell 8.6% and 20%, respectively.

The Healthcare segment recorded revenues of €3.9 billion compared to €3.8 billion in the corresponding period last year. Both the divisions of Healthcare – pharmaceuticals and consumer health contributed to the growth of the Healthcare segment. Bayer’s primary market, Europe – accounting for 39% of its Healthcare revenues – declined 3%, compared to the year-ago period. The other markets of North America,

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

DrStockPick.com Watch List!

My Picks for Monday September 28, 2009, are:

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

PWRM’s NuroPro PD test was developed to help clinicians distinguish patients with Parkinson’s disease from “normal” individuals and patients with other neurological disorders. The NuroPro PD test, developed by Power3, utilizes a panel of blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability that a

...

The shape of the global market for pharmaceuticals is undergoing a rapid change. As recently as 2006, more than half of the market growth was in the United States. This data comes from IMS Health, a consultancy which is a leading provider of pharmaceutical trends.

However, the necessity for the pharmaceutical industry to develop new markets is urgent. The latest forecasts from IMS Health suggests that global sales in the industry will grow by just 2.5 – 3.5 percent this year, the smallest expansion it has ever recorded. The United States – which still accounts for two-fifths of all revenues – will decline by 1-2 percent.

The figures from IMS Health did highlight one source of optimism for pharmaceutical companies – the seven countries IMS Health calls the “pharemerging countries” – China, Brazil, India, Russia, Turkey, South Korea and Mexico. The potential for the pharma companies to increase their revenues is enormous

...

Emerging Market for Pharma

Tony Daltorio, The Investment U Research Team

The shape of the global market for pharmaceuticals is undergoing a rapid change.

As recently as 2006, more than half of the market growth was in the United States. This data comes from IMS Health, a consultancy that is a leading provider of pharmaceutical trends.

However, the necessity for the pharmaceutical industry to develop new markets is urgent. The latest forecasts from IMS Health suggests that global sales in the industry will grow by just 2.5 – 3.5 percent this year, the smallest expansion it has ever recorded. The United States – which still accounts for two-fifths of all revenues – will decline by 1-2 percent.

Many large pharma companies are now realizing that a lot of future growth is likely to occur outside of what used to be

...

Allergan, Inc. (AGN) once again beat expectations by posting a second-quarter profit of 75 cents per share (up 19% year over year), which was well above the Zacks Consensus Estimate of 68 cents per share. Profits were primarily driven by cost management and efficiencies. However, total revenues declined 3.6% to $1130.8 million in the reported quarter. Specialty pharmaceuticals sales declined 0.6% to $921.2 million. Eyecare pharmaceutical sales declined 2.5%. The strong performance of products like the Alphagan franchise, Lumigan, Combigan and Restasis was offset by weakness in the artificial tears segment. Botox sales declined 3.2% to $336.8 million. In addition to weak consumer spending, we believe negative news surrounding Botox’ safety record have affected sales. Going forward, we expect Botox sales to continue declining especially in the face of additional competition from Medicis Pharma’s (MRX) Dysport, which was launched recently in the U.S. Meanwhile, ...

On July 28, 2009, Teva Pharmaceutical Industries Ltd. (TEVA) reported financial results for the second quarter ended June 30, 2009. Net sales increased 20% y-o-y to $3.4 billion in the reported quarter, missing the consensus estimate by a small margin. The strengthening U.S. dollar adversely impacted net sales by $256 million or 9%. Non-GAAP net income increased 25% to $742 million. Non-GAAP EPS of $0.83 (up 15% y-o-y) exceeded our and consensus estimate of $0.81 and $0.80, respectively. Strong sales, improved gross margins (due to better product mix) and lower-than-expected R&D expenses helped drive earnings in the reported quarter. GAAP net income declined 2.3% to $521 million or $0.58 per share. Revenue performance across key business segments was mixed. While total pharmaceutical sales increased 22% y-o-y to about $3.3 billion in the reported quarter, total API business sales declined 13% y-o-y to $135 million. The ...

In a Schedule 14A proxy statement filed on May 20, 2009 Merck & Co. (MRK) disclosed that it had received notification from Johnson & Johnson's (JNJ) Centocor subsidiary of its intention to terminate, through arbitration, the distribution agreement with Schering-Plough Corp (SGP) for Remicade and golimumab (Simponi). As we detailed in prior reports and blogs, we had expected some sort of challenge from J&J, so the recent news comes as no surprise.In March 2009 Merck and Co. and Schering-Plough announced a merger agreement whereby the companies would combine in a deal currently valued at approximately $48.8 billion. The deal was structured as a "reverse-merger" with Schering-Plough being the surviving entity. Merck believes that the "reverse-merger" structure will avoid triggering a change-of-control provision in Schering-Plough's agreement with J&J relative to rights to Remicade and golimumab.J&J discovered both compounds and licensed ex-U.S. marketing rights ...

This morning Bristol-Myers Squibb (BMY) announced financial results for the 4th quarter and issued 2009 financial guidance. Fourth quarter revenue of $5.25 billion increased by 4% from the same period in 2007, and below our estimate of $5.44 billion. Operational revenue growth remained strong, up 8%, but the negative effects of foreign exchange [FX] impacted revenue growth by 4%.Pharmaceutical sales increased by 4% in the quarter to $4.5 billion while the nutritional business posted sales of $707 million, up 6% from the 4th quarter of 2007. U.S. pharmaceutical sales increased by 13% in the quarter while international pharmaceutical sales fell 9%, primarily as a result of an 8% FX headwind.EPS, adjusted for certain non-recurring items including the gain on sales of ImClone shares in the quarter, was $0.46, and well ahead of our estimate of $0.39. EPS increased by 53% over the $0.30 posted ...

By Rob Fannon, editor, Phase 1 Investor

Genentech has reigned as king of the biotech industry for more than three decades.

A three-hour chat in a San Francisco pub launched the company in 1976. On its first day of trading in 1980, the stock tripled – and has risen 20-fold since. Today, Genentech’s portfolio includes three of the world’s top-selling biotech drugs – Avastin ($2.5 billion per year), Herceptin ($1.7 billion), and Rituxan ($2.5 billion).

But the king of biotech is now a buyout target. While I don’t believe the takeout bodes well for buyer or seller, the deal should mean big profits for biotech investors. Let me explain…

In 1990, Swiss drug company Roche acquired a majority stake in Genentech. Roche became Genentech’s exclusive European distributor. Today, Genentech’s drugs represent 30% of Roche’s pharmaceutical sales. And as Genentech’s largest shareholder, Roche has multiplied its money about 40

...